drugset / Trial / NCT02544425
VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)
NaSingle-groupOpen-labelTreatment
Summary
Open-labeled, multicenter phase II study of VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation in patients with stage III/IV extranodal NK/T-cell Lymphoma.
Timeline
- Start
- 2016-02-21
- Primary completion
- 2021-08-31
- Completion
- 2021-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Busulfan | Small molecule | 3.2 mg/kg | — |
| Subject | Dexamethasone | Small molecule | 40 mg | Oral |
| Subject | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Ifosfamide | Small molecule | 1200 mg/m2 | Intravenous |
| Subject | Melphalan | Small molecule | 70 mg/m2 | — |
| Subject | asparaginase | Protein / enzyme biologic | 4000 unknown | Intramuscular |